RT Journal Article
SR Electronic
T1 Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study.
JF Journal of Neurology, Neurosurgery & Psychiatry
JO J Neurol Neurosurg Psychiatry
FD BMJ Publishing Group Ltd
SP 248
OP 252
DO 10.1136/jnnp.59.3.248
VO 59
IS 3
A1 L H Van den Berg
A1 H Kerkhoff
A1 P L Oey
A1 H Franssen
A1 I Mollee
A1 M Vermeulen
A1 F G Jennekens
A1 J H Wokke
YR 1995
UL http://jnnp.bmj.com/content/59/3/248.abstract
AB The effect of high dose intravenous immunoglobulin (IVIg) treatment was studied in six patients with multifocal motor neuropathy (MMN). All patients responded to treatment (0.4 g/kg for five consecutive days) in an open trial. The effect of IVIg treatment was confirmed for each patient in a single patient, double blind, placebo controlled trial. Four patients received two IVIg treatments and two placebo treatments, and two patients received one IVIg and one placebo treatment in a randomised order. Five out of six patients responded to IVIg but not to placebo. One patient responded to IVIg in the same manner as to placebo treatment. Thus IVIg treatment can lead to improvement of muscle strength in patients with MMN.